News - Janssen-Cilag, Adcetris

Filter

Current filters:

Janssen-CilagAdcetris

Popular Filters

1 to 25 of 38 results

Janssen’s Sirturo gets conditional EU approval for multi-resistant TB

Janssen’s Sirturo gets conditional EU approval for multi-resistant TB

10-03-2014

US health care giant Johnson & Johnson’s European subsidiary Janssen-Cilag has been granted conditional…

Antibiotics and Infectious diseasesEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationSirturo

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Takeda's lymphoma drug Adcetris approved in Japan

Takeda's lymphoma drug Adcetris approved in Japan

18-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical has received approval from the country’s Ministry…

AdcetrisFinancialOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma

12-11-2013

In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

Janssen-Cilag submits EMA Marketing Authorization for ibrutinib

Janssen-Cilag submits EMA Marketing Authorization for ibrutinib

31-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International has submitted a Marketing…

ibrutinibJanssen-CilagNorth AmericaOncologyPharmaceuticalRegulation

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

Seattle Genetics highlights Adcetris clinical data in the frontline setting

13-10-2013

US biotech firm Seattle Genetics has highlighted multiple Adcetris (brentuximab vedotin) data presentations…

AdcetrisBiotechnologyOncologyResearchSeattle Genetics

EU backs wider use of Velcade

09-08-2013

The European Commission has approved the use of Johnson & Johnson (NYSE: JNJ) European subsidiary Janssen-Cilag's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Janssen files for European approval of hep C candidate simeprevir

25-04-2013

Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

Seattle Genetics files sBLA for Adcetris in relapsed Hodgkin lymphoma and systemic ALCL

19-03-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) has submitted a supplemental Biologics License Application…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis

01-02-2013

The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

Expanded indication for Janssen's Zytiga cleared in EU

14-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International said Friday…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationZytiga

FDA grants Seattle Genetics' Adcetris orphan rating in MF

27-11-2012

US biotech firm Seattle Genetics (Nasdaq: SGEN) says its Adcetris (brentuximab vedotin) has been granted…

AdcetrisBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Takeda debuts Hodgkin lymphoma drug Adcetris in UK

19-11-2012

Japan's largest drugmaker, Takeda Pharmaceuticals (TYO: 4502), this morning announced the launch UK of…

AdcetrisEuropeMarkets & MarketingOncologyPharmaceuticalTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris

01-11-2012

Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Janssen-Cilag files for EU approval of bedaquiline in MDR-TB

02-09-2012

Johnson & Johnson (NYSE: JNJ) Belgium-based subsidiary Janssen-Cilag International submitted a Marketing…

Antibiotics and Infectious diseasesbedaquilinedelamanidEuropeJanssen-CilagJohnson & JohnsonOtsukaPharmaceuticalRegulation

CHMP positive on first gene therapy, Glybera; and more opinions

23-07-2012

Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

Johnson & Johnson pulls EU submission for Velcade use in NHL

05-07-2012

The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

1 to 25 of 38 results

Back to top